Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two small molecule drugs, sodium benzoate and N-acetylcysteine (NAC). Sodium benzoate acts primarily as a glycine scavenger by conjugating with glycine in the liver to form hippurate, which is then excreted in urine. This mechanism underlies its use in disorders such as non-ketotic hyperglycinemia and urea cycle disorders[5]. N-acetylcysteine is a precursor to glutathione, serving as an antioxidant and mucolytic agent. It also modulates glutamatergic neurotransmission via effects on cystine-glutamate exchange and has anti-inflammatory properties[6][7][8]. The combination has been studied for potential additive or synergistic effects on oxidative stress pathways, inflammation, NMDA receptor modulation, and neuroprotection—particularly in neuropsychiatric conditions like schizophrenia[1]. Both agents are well-tolerated individually; their combined use remains investigational.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium benzoate + n-acetylcysteine.